Showing posts with label Primary Care. Show all posts
Showing posts with label Primary Care. Show all posts

Friday, 9 October 2015

PubMed Update September 2015

Twelve this month. Enjoy!

Ries R, Krupski A, West II, Maynard C, Bumgardner K, Donovan D, Dunn C, Roy-Byrne P.
J Addict Med. 2015 Oct;9(5):417-26. doi: 10.1097/ADM.0000000000000151.
Comment: Can’t access the full article, but the abstract suggests a fascinating look into opioid-using safety net primary care patients.

Kazour F, Soufia M, Rohayem J, Richa S.
Community Ment Health J. 2015 Sep 30. [Epub ahead of print]
Comment: Most studies of heroin users find that heroin is *not* the usual method of suicide attempts. Interestingly, this study finds something quite different, with nearly half of attempts being through heroin use in Lebanon.

Roxburgh A, Hall WD, Burns L, Pilgrim J, Saar E, Nielsen S, Degenhardt L.
Med J Aust. 2015 Oct 5;203(7):299.
Comment: Interesting paper exploring deaths related to one, low-potency, opioid. Those deaths seemed to be increasing, over a third were intentional (that’s much higher than other opioids), and a remarkably high proportion were polydrug – which makes sense since it would be tough to die from codeine alone.

Kampman K, Jarvis M.
J Addict Med. 2015 Oct;9(5):358-67. doi: 10.1097/ADM.0000000000000166.
Comment: Another that I can’t access but whose abstract looks compelling.

Kharasch ED, Regina KJ, Blood J, Friedel C.
Anesthesiology. 2015 Sep 19. [Epub ahead of print]
Comment: Ah, the complexities of methadone. Genetic differences in hepatic metabolism are more prominent in oral than intravenous methadone.


Kimber J, Larney S, Hickman M, Randall D, Degenhardt L.
Lancet Psychiatry. 2015 Sep 15. pii: S2215-0366(15)00366-1. doi: 10.1016/S2215-0366(15)00366-1. [Epub ahead of print]
Comment: There is likely a mortality benefit to buprenorphine in the initiation of treatment, but after that methadone and buprenorphine are comparable. I’ll admit that I’m a bit surprised by that – I would have expected an ongoing relative benefit to buprenorphine (there was a possible benefit to buprenorphine in all-cause mortality during the treatment time). Of note for treatment programs, even if the eventual treatment is methadone, it may be possible to avert the initiation mortality risk by starting with buprenorphine because the subsequent switch to methadone doesn’t come with the mortality risk.

Sumner SA, Mercado-Crespo MC, Spelke MB, Paulozzi L, Sugerman DE, Hillis SD, Stanley C.
Prehosp Emerg Care. 2015 Sep 18:1-6. [Epub ahead of print]
Comment: Really interesting analysis of medical examiner records. They looked at opioid overdose decedents who had undergone resuscitation efforts and then looked to see if they had received naloxone during those paramedic efforts. Naloxone was given in two-thirds of cases and was much more likely to be given to younger men with evidence of illicit drug use. Should paramedics be more willing to use naloxone in settings that don’t look like a “classic heroin overdose”? Or would that have negative effects? This is a really interesting topic for emergency medicine.

Winston I, McDonald R, Tas B, Strang J.
BMJ Case Rep. 2015 Sep 14;2015. pii: bcr2015210391. doi: 10.1136/bcr-2015-210391.
Comment: I can’t access this but the abstract purports that it is the “first-ever account” of a lay person titrating naloxone to respiratory function. Not to be snooty, but that’s really old news.

Fischer B, Murphy Y, Rudzinski K, MacPherson D.
Int J Drug Policy. 2015 Aug 14. pii: S0955-3959(15)00242-X. doi: 10.1016/j.drugpo.2015.08.007. [Epub ahead of print]
Comment: Canada’s conflicted drug policy.

Michel L, Lions C, Maradan G, Mora M, Marcellin F, Morel A, Spire B, Roux P, Carrieri PM; Methaville Study Group.
Compr Psychiatry. 2015 Oct;62:123-31. doi: 10.1016/j.comppsych.2015.07.004. Epub 2015 Jul 14.
Comment: Methadone patients with HCV are at *way* higher risk for suicide. Increasingly, studies suggest that there are real mental health costs to HCV and corresponding benefits to HCV treatment.

Fulton-Kehoe D, Sullivan MD, Turner JA, Garg RK, Bauer AM, Wickizer TM, Franklin GM.
Med Care. 2015 Aug;53(8):679-85. doi: 10.1097/MLR.0000000000000384.
Comment: The increasing risk of overdose with opioid dose is likely about linear and just knowing dose or dosing frequency/duration doesn’t tell you the whole picture. Unfortunately big data just doesn’t answer the deep questions about substance use.

Ahmad SA, Scolnik D, Snehal V, Glatstein M.
Am J Ther. 2015 Jan-Feb;22(1):e14-6. doi: 10.1097/MJT.0b013e318293b0e8. Review.
Comment: I can’t access the full article, but am not surprised that naloxone doesn’t reverse clonidine toxicity.

Monday, 9 September 2013

PubMed Update August 2013


16 papers today – this is getting to be a big job. Naloxone, fentanyl, methadone, stars, pain, Central Asia, primary care, injection facilities, personal stories …

Centers for Disease Control and Prevention (CDC).
MMWR Morb Mortal Wkly Rep. 2013 Aug 30;62(34):703-4.
Comment: The evidence of synthetic fentanyl was difficult to detect and concerning to many as heralding a possible repeat of the 2006/2007 fentanyl-tainted heroin overdose outbreak.

Saifan C, Glass D, Barakat I, El-Sayegh S.
Case Rep Med. 2013;2013:242730. doi: 10.1155/2013/242730. Epub 2013 Jul 29.
Comment: In this case the patient was restarted on methadone and the sensorineural hearing loss was permanent.

Chaparro LE, Furlan AD, Deshpande A, Mailis-Gagnon A, Atlas S, Turk DC.
Cochrane Database Syst Rev. 2013 Aug 27;8:CD004959. doi:
Comment: There are no quality data to support long-term management of non-cancer pain with opioids.

Willens JS.
Pain Manag Nurs. 2013 Sep;14(3):125. doi: 10.1016/j.pmn.2013.07.004. No abstract available.
Comment: The Glee star.


Shadnia S, Rahimi M, Hassanian-Moghaddam H, Soltaninejad K, Noroozi A.
Clin Toxicol (Phila). 2013 Aug 23. [Epub ahead of print]
Comment: Accidental poisonings among family in Iran for (insufficiently-labeled) take-home methadone syrup.

Teo A, Cooper J.
Scott Med J. 2013 Aug;58(3):149-53. doi: 10.1177/0036933013496951.
Comment: I’m unable to access this paper. It’s a review of overdose events at a Scottish hospital; 4% were administered naloxone.

Gilbert L, Primbetova S, Nikitin D, Hunt T, Terlikbayeva A, Momenghalibaf A, Ruziev M, El-Bassel N.
Drug Alcohol Depend. 2013 Aug 13. doi:pii: S0376-8716(13)00282-2.
Comment: A really interesting approach to thinking about HIV and drug overdose mortality, through the lens of syndemics – a hot topic in public health – and risk environments. With the bonus of an important review of data from several Central Asian states.

Bernstein HG, Trübner K, Krebs P, Dobrowolny H, Bielau H, Steiner J, Bogerts B.
Acta Histochem. 2013 Aug 13. doi:pii: S0065-1281(13)00145-1.
Comment: Interesting analysis comparing heroin overdose patients to controls, although I’m unclear it’s direct relationship to the pathologic processes of overdose.

Heimer R, Barbour R, Palacios WR, Nichols LG, Grau LE.
AIDS Behav. 2013 Aug 7. [Epub ahead of print]
Comment: Intriguing paper on rural heroin use.

Chahua M, Sordo L, Barrio G, Domingo-Salvany A, Brugal MT, Molist G, de la Fuente L, Bravo MJ.
Eur Addict Res. 2013 Aug 1;20(1):1-7. [Epub ahead of print]
Comment: There haven’t been many overdose studies out of Spain. Nice to see this.

Bowman S, Eiserman J, Beletsky L, Stancliff S, Bruce RD.
Am J Med. 2013 Jul;126(7):565-71. doi: 10.1016/j.amjmed.2012.11.031. Epub 2013 May 8. Review.
Comment: Kudos to the authors for getting out to primary care providers information on simple harm reduction practices that can be employed in clinical settings.

Taylor R Jr, Pergolizzi JV Jr, Porreca F, Raffa RB.
Expert Opin Investig Drugs. 2013 Apr;22(4):517-25. doi: 10.1517/13543784.2013.778973. Review.
Comment: Fascinating paper on the analgesic properties of opioid ANTagonists.

Jozaghi E, Andresen MM.
Harm Reduct J. 2013 Feb 16;10:1. doi: 10.1186/1477-7517-10-1.
Comment: A discussion including the benefits of supervised injection facilities in reducing overdose deaths, sharing of injection equipment, public drug use, and utilization of emergency medical services.

Algren DA, Monteilh CP, Punja M, Schier JG, Belson M, Hepler BR, Schmidt CJ, Miller CE, Patel M, Paulozzi LJ, Straetemans M, Rubin C.
J Med Toxicol. 2013 Mar;9(1):106-15. doi: 10.1007/s13181-012-0285-4.
Comment: A review of pathological details related to the tragic 2005-2007 fentanyl-tainted heroin outbreak.

George S, Boulay S, Begley D.
BMJ Case Rep. 2010 Sep 7;2010. doi:pii: bcr0520102986.
Comment: A rare example in the medical literature, this paper includes several paragraphs of direct patient perspective on administering naloxone. Read the free full-text from BMJ.

Reece AS.
BMJ Case Rep. 2010 Sep 7;2010. doi:pii: bcr0420102871. 10.1136/bcr.04.2010.2871. Review.
Comment: The hepatotoxicity concerns with naltrexone were based on doses of around 2 grams, which would be considered massive today.

Tuesday, 11 June 2013

PubMed Update May 2013


Here is the May 2013 roundup with 7 papers and some extra kudos to the authors for important steps forward in data or practice.


Llorente J, Withey S, Rivero G, Cunningham M, Cooke A, Saxena K, McPherson J, Oldfield S, Dewey W, Bailey C, Kelly E, Henderson G.
Mol Pharmacol. 2013 May 28. [Epub ahead of print]

Comments: Intriguing analysis of ethanol and morphine, suggesting that alcohol may enhance the effects of morphine. Could this account for some of the risk of combining opioids with alcohol?


Moryl N, Pope J, Obbens E.
J Opioid Manag. 2013 Jan-Feb;9(1):29-34. doi: 10.5055/jom.2013.0144.

Comments: One of a handful of issues with methadone dosing that may have factored into the challenges encountered by providers and patients with this drug when used for pain.


Schuman-Olivier Z, Hoeppner BB, Weiss RD, Borodovsky J, Shaffer HJ, Albanese MJ.
Drug Alcohol Depend. 2013 May 17. doi:pii: S0376-8716(13)00133-6. 10.1016/j.drugalcdep.2013.04.006. [Epub ahead of print]

Comments: For patients on any opioid medications, benzodiazepines are associated with an increased risk of overdose. This study of 328 buprenorphine maintenance patients didn’t find an association with benzodiazepine prescriptions and overdose, but did find an association with more frequent emergency department visits and injury-related ED visits. We may never learn if benzodiazepines are causal in this pathway or merely a marker, but these data do contribute to the overall concern.


Horyniak D, Dietze P, Degenhardt L, Higgs P, McIlwraith F, Alati R, Bruno R, Lenton S, Burns L.
Drug Alcohol Depend. 2013 May 9. doi:pii: S0376-8716(13)00116-6. 10.1016/j.drugalcdep.2013.03.021. [Epub ahead of print]

Comments: More excellent work from this team. I particularly appreciate the estimate of the reduction in overdose risk with age. In a mathematical model of overdose, we estimated a 50% reduction in the risk of overdose over 10 years of use, whereas this paper suggests the figure is closer to 20% - data that will be very helpful in future iterations.


Bowman S, Eiserman J, Beletsky L, Stancliff S, Bruce RD.
Am J Med. 2013 May 8. doi:pii: S0002-9343(13)00138-1. 10.1016/j.amjmed.2012.11.031. [Epub ahead of print]

Comments: Congratulations to this team on producing what I think are the first primary care guidelines in the scientific literature recommending overdose prevention and naloxone for at-risk patients.


McCormick Z, Chu SK, Chang-Chien GC, Joseph P.
Pain Med. 2013 May 3. doi: 10.1111/pme.12135. [Epub ahead of print]

Comments: Less an overdose article per se, but a paper that pays attention to the overdose issue when titrating opioids.


Green TC, Bowman SE, Zaller ND, Ray M, Case P, Heimer R.
Subst Use Misuse. 2013 May;48(7):558-67. doi: 10.3109/10826084.2013.787099.

Comments: A qualitative look at providers feelings about providing naloxone to “drug users” and, separately, to “pain patients.” This is a great and useful analysis – and honestly surprisingly positive across the board. The major concern raised seemed to be that naloxone not be the onlything done to try to reduce overdose. This is a pretty dramatic shift in attitudes since earlier evaluations of provider opinion on lay naloxone (Beletsky et al 2007, Coffin et al 2003).